Cambridge, Massachusetts-based biotech company Mersana Therapeutics has closed $33 million in Series C financing. Wellington Management Company led the round with participation from other investors that included Cormorant Asset Management, Arrowpoint Partners, Takeda Pharmaceutical Company Limited, New Enterprise Associates and Rock Springs Capital.
Source: Press Release